SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-21-039669
Filing Date
2021-11-29
Accepted
2021-11-29 16:45:15
Documents
12
Period of Report
2021-11-26
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K brhc10031303_8k.htm   iXBRL 8-K 27299
  Complete submission text file 0001140361-21-039669.txt   168265

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20211126.xsd EX-101.SCH 3935
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20211126_lab.xml EX-101.LAB 23288
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20211126_pre.xml EX-101.PRE 16558
5 EXTRACTED XBRL INSTANCE DOCUMENT brhc10031303_8k_htm.xml XML 4389
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 211456872
SIC: 2834 Pharmaceutical Preparations